Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
OXFORDSHIRE, United Kingdom, Dec. 18, 2017 -- OxStem Limited today announced that its senior management team will be presenting at the Biotech Showcase conference and will subsequently host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.
To schedule a meeting with OxStem, investors can register on the online system managed by the Company’s US investor relations firm, LifeSci Advisors, LLC, or make a request via e-mail at [email protected].
About OxStem Limited
OxStem is a discovery phase biotechnology company positioned to transform the field of medical therapeutics for what are typically (but not exclusively) age-related conditions. OxStem is developing novel classes of drugs that stimulate endogenous stem and progenitor cells in the body – augmenting existing cellular repair/regeneration processes or ‘re-wiring’ defunct processes.
OxStem has programs in neurodegenerative disease, heart disease, blindness and cancer, with the intention of establishing two new programs in H1 2018 in diabetes and wound healing/inflammation. OxStem, a spin-out from the University of Oxford, operates a distributed R&D model, with programs conducted within disease-focused subsidiary companies, each working in partnership with the University of Oxford.
OxStem’s disruptive discovery engine leverages the world-class expertise of the University of Oxford and is comprised of an internationally respected top tier scientific team. OxStem’s co-founding scientists have a strong track record in commercializing world-class scientific innovation.
Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
617-535-7746
